SJEPD031285_D1.RNA-Seq
EPN · EPN Tumor
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- EPN Tumor
- cancer_type
- EPN
- subtype
- EPN Tumor
- age_years
- 1.65
- e1_e2
- E2
- umap1_2d
- -5.167203781
- umap2_2d
- 0.830143175
- umap1_3d
- -0.729652363
- umap2_3d
- 3.047741528
- umap3_3d
- 0.223240486
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.660
- IL6_JAK_STAT3_SIGNALING+0.650
- INTERFERON_GAMMA_RESPONSE+0.630
- INFLAMMATORY_RESPONSE+0.580
- INTERFERON_ALPHA_RESPONSE+0.580
- ALLOGRAFT_REJECTION+0.570
- COMPLEMENT+0.510
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.510
- ANDROGEN_RESPONSE+0.480
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.480
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.300
- G2M_CHECKPOINT-0.220
- E2F_TARGETS-0.210
- DNA_REPAIR-0.140
- NOTCH_SIGNALING-0.110
- KRAS_SIGNALING_DN-0.100
- SPERMATOGENESIS-0.090
- HEDGEHOG_SIGNALING-0.050
- MYC_TARGETS_V2+0.070
- MITOTIC_SPINDLE+0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_T0RKFEKR | pilocytic astrocytoma | — | 0.948 |
| 2 | s_150324_4b | EPN | Posterior Fossa EPN | 0.942 |
| 3 | MDT-AP-0173 | Med | Medulloblastoma | 0.936 |
| 4 | SRR934945 | — | — | 0.933 |
| 5 | BS_WRHDP7WF | EPN | Posterior Fossa EPN | 0.931 |
| 6 | SJEPD031215_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.929 |
| 7 | BS_VARR255N | pilocytic astrocytoma | — | 0.929 |
| 8 | 53D8CF8D-31BA-4CB8-A14F-5C9AB9554F5D | — | — | 0.921 |
| 9 | MNG202 | — | — | 0.920 |
| 10 | SRR934924 | — | — | 0.920 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.660 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.650 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.630 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.580 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.580 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.570 | Idelalisib | — uncovered |
| COMPLEMENT | 0.510 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.510 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.480 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.480 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.460 | Remibrutinib | — uncovered |
| COAGULATION | 0.460 | Binimetinib | — uncovered |
| HYPOXIA | 0.460 | Idelalisib | — uncovered |
| APOPTOSIS | 0.450 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.430 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.410 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.410 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.390 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.390 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.370 | Remibrutinib | — uncovered |